Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-10 · 44 (10) · 2143-2153
DOI: 10.1161/atvbaha.124.319864 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-10. Verfasst von Richard J Travers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cardiology Research Institute (R.J.T., A.S., I.Z.J.), Tufts Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Proto-Oncogene Mas, Antineoplastic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Kinase inhibitors (KIs) targeting oncogenic molecular pathways have revolutionized cancer therapy. By directly targeting specific tumor-driving kinases, targeted therapies have fewer side effects compared with chemotherapy. Despite the enhanced specificity, cardiovascular side effects have emerged with many targeted cancer therapies that limit long-term outcomes in patients with cancer. Endothelial cells lining all blood vessels are critical to cardiovascular health and are also exposed to circulating levels of systemic anticancer therapies. Both on- and off-target perturbation of signaling pathways from KIs can cause endothelial dysfunction, resulting in cardiovascular toxicity. As such, the endothelium is a potential source, and also a therapeutic target for prevention, of cardiovascular toxicity. In this review, we examine the evidence for KI-induced endothelial cell dysfunction as a mechanism for the cardiovascular toxicities of vascular endothelial growth factor inhibitors, BCR-Abl (breakpoint cluster region-Abelson proto-oncogene) KIs, Bruton tyrosine inhibitors, and emerging information regarding endothelial toxicity of newer classes of KIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Cardiology Research Institute (R.J.T., A.S., I.Z.J.), Tufts Medical Center, Boston, MA.
- Division of Hematology and Oncology (R.J.T.), Tufts Medical Center, Boston, MA.
ORCID-Profile: Richard J Travers, Alec Stepanian, Iris Z Jaffe
Förderung
- American Heart Association-American Stroke Association
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Travers, R. J., Stepanian, A., & Jaffe, I. Z. (2024). Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(10), 2143-2153. https://doi.org/10.1161/atvbaha.124.319864
Vancouver
Travers RJ, Stepanian A, Jaffe IZ. Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(10):2143-2153. doi:10.1161/atvbaha.124.319864
BibTeX
@article{Travers2024,
author = {Travers, Richard J and Stepanian, Alec and Jaffe, Iris Z},
title = {Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {10},
pages = {2143--2153},
doi = {10.1161/atvbaha.124.319864}
}
EUVIMED